Tema Etfs LLC Invests $1.16 Million in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)

Tema Etfs LLC acquired a new stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 61,503 shares of the biotechnology company's stock, valued at approximately $1,156,000.

Several other institutional investors also recently bought and sold shares of the company. Silvercrest Asset Management Group LLC increased its stake in Arrowhead Pharmaceuticals by 24.7% in the 4th quarter. Silvercrest Asset Management Group LLC now owns 280,511 shares of the biotechnology company's stock valued at $5,274,000 after buying an additional 55,622 shares during the period. Sphera Funds Management LTD. purchased a new stake in shares of Arrowhead Pharmaceuticals during the 4th quarter worth $3,714,000. ProShare Advisors LLC boosted its position in shares of Arrowhead Pharmaceuticals by 28.3% during the 4th quarter. ProShare Advisors LLC now owns 45,330 shares of the biotechnology company's stock worth $852,000 after purchasing an additional 10,005 shares in the last quarter. Nomura Holdings Inc. boosted its position in shares of Arrowhead Pharmaceuticals by 54.1% during the 4th quarter. Nomura Holdings Inc. now owns 16,466 shares of the biotechnology company's stock worth $310,000 after purchasing an additional 5,781 shares in the last quarter. Finally, Millennium Management LLC boosted its position in shares of Arrowhead Pharmaceuticals by 41.7% during the 4th quarter. Millennium Management LLC now owns 914,550 shares of the biotechnology company's stock worth $17,194,000 after purchasing an additional 268,946 shares in the last quarter. 62.61% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have commented on ARWR shares. Royal Bank of Canada restated an "outperform" rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. B. Riley restated a "buy" rating and set a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. Chardan Capital reaffirmed a "buy" rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Citigroup decreased their price objective on shares of Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a research report on Tuesday, May 13th. Finally, HC Wainwright reiterated a "buy" rating and issued a $80.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday. Four research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, Arrowhead Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $42.13.

Insider Buying and Selling at Arrowhead Pharmaceuticals

In other news, CEO Christopher Richard Anzalone sold 133,333 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $17.02, for a total transaction of $2,269,327.66. Following the transaction, the chief executive officer now directly owns 3,773,802 shares in the company, valued at $64,230,110.04. This represents a 3.41% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last ninety days, insiders have sold 275,880 shares of company stock worth $4,034,037. Corporate insiders own 4.30% of the company's stock.

Arrowhead Pharmaceuticals Trading Up 3.5%

NASDAQ:ARWR traded up $0.55 on Tuesday, reaching $16.29. The stock had a trading volume of 1,940,733 shares, compared to its average volume of 1,491,372. The company has a market cap of $2.25 billion, a price-to-earnings ratio of -3.15 and a beta of 0.89. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. The firm's fifty day moving average is $13.33 and its two-hundred day moving average is $17.75. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $9.57 and a 12-month high of $30.41.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its earnings results on Monday, May 12th. The biotechnology company reported $2.75 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.06) by $2.81. The firm had revenue of $542.71 million during the quarter, compared to analysts' expectations of $116.27 million. During the same quarter last year, the company posted ($1.02) earnings per share. Equities analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current fiscal year.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.